Semaglutide Beneficial for Hidradenitis Suppurativa in Patients With Obesity
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Sept. 25, 2024 -- For patients with obesity, the addition of semaglutide to standard hidradenitis suppurativa (HS) treatments yields improvement in quality of life and a reduction in flares, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.
Daniel Lyons, M.D., from St. Vincent's University Hospital in Dublin, and colleagues reported the impact of semaglutide on disease control and quality of life among 30 patients with obesity (27 female and three male) from an HS clinic.
All of the patients were prescribed concomitant HS treatments. The researchers found that the mean duration of semaglutide treatment was 8.2 months and the mean dose was 0.8 mg once weekly. There was a decrease seen in mean body mass index, from 43.1 to 41.5 kg/m2. In addition, the mean weight decreased from 117.7 to 111.6 kg. Overall, 33.33 percent of the patients lost ≥10 kg during the study period. The mean frequency of patient-reported flares decreased from once every 8.5 weeks to once every 12 weeks following commencement of semaglutide, with a reduction in the mean Dermatology Life Quality Index (DLQI) from 13/30 to 9/30. A DLQI reduction of 4 points or more, equal to or surpassing the minimal clinically important difference, occurred in one-third of patients. There was also a significant reduction in hemoglobin A1c (from 39.3 to 36.6).
"We hope our preliminary data will encourage dermatologists to consider weight loss medication as an adjunct to existing HS treatments," Lyons said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related...
Post-Kidney Transplant Adverse Outcomes Increased With BMI-BSA Obesity
TUESDAY, May 27, 2025 -- Combined body mass index (BMI)-body surface area (BSA) obesity is associated with an increased risk for post-kidney transplant (KT) adverse outcomes...
Semaglutide Plus Intensive Behavioral Therapy Most Beneficial for Weight Loss
FRIDAY, May 23, 2025 -- Weight loss treatment combining personalized semaglutide with intensive behavioral therapy (IBT) yields weight loss similar to that reported in...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.